Drug intelligence / Profile preview

7MW4811

Development stage: Preclinical
Lead developer: Mabwell
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

7MW4811 is an antibody-drug conjugate (ADC) developed by Mabwell (Shanghai) Bioscience Co., Ltd. utilizing their proprietary next-generation IDDC™ platform. The molecule consists of a monoclonal antibody conjugated to Mtoxin™ (MF6), a novel topoisomerase I inhibitor payload. In preclinical studies, 7MW4811 has demonstrated potent anti-tumor activity across various solid tumor models, including lung, colorectal, pancreatic, and gastric cancers, with notable efficacy observed in gastrointestinal malignancies. The drug was featured at the 15th World ADC Conference in 2024, highlighting its potential as a therapeutic candidate for advanced solid tumors.

Targets

TOP1 (DNA Topoisomerase I)

Beyond the preview

Go deeper on 7MW4811.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 7MW4811.

Explore the full profile